ANDCo-Promotion Agreement • March 10th, 2006 • Atherogenics Inc • Pharmaceutical preparations • New York
CO-PROMOTION AGREEMENT by and between TYME TECHNOLOGIES, INC. And EAGLE PHARMACEUTICALS, INC. January 7, 2020Co-Promotion Agreement • May 22nd, 2020 • Tyme Technologies, Inc. • Pharmaceutical preparations • Delaware
This Co-Promotion Agreement (this “Agreement”) is entered into and dated as of January 7, 2020 (the “Effective Date”) by and between Tyme Technologies, Inc., a Delaware corporation (“TYME”), and Eagle Pharmaceuticals, Inc., a Delaware corporation (“Eagle”). TYME and Eagle are each referred to individually as a “Party” and together as the “Parties”.
Portions of this exhibit marked [*] are requested to be treated confidentially. CO-PROMOTION AGREEMENTCo-Promotion Agreement • August 22nd, 2005 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • Delaware
This CO-PROMOTION AGREEMENT (this “Agreement”), dated March 2, 2005, is entered into by and between SALIX PHARMACEUTICALS, INC., a California corporation (“Salix”) and ALTANA PHARMA US, INC., a Delaware corporation (“Altana”).
Confidential treatment requested under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2. The confidential portions of this exhibit have been omitted and are marked accordingly. The confidential portions have been filed separately with the Securities and...Co-Promotion Agreement • November 2nd, 2012 • Auxilium Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Co-promotion Agreement (hereafter, the “Agreement”) is entered into as of May 18, 2012, by and between Auxilium Pharmaceuticals, Inc., a Delaware corporation (“Auxilium”), and GlaxoSmithKline LLC, a Delaware limited liability company (“GSK”).
CO-PROMOTION AGREEMENTCo-Promotion Agreement • November 30th, 2016 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Co-Promotion Agreement (this “Agreement”) is entered into as of November 4, 2015 (the “Effective Date”), by and between Eagle Pharmaceuticals, Inc., a corporation organized under the laws of Delaware with offices at 50 Tice Blvd., Suite 315, Woodcliff Lake, NJ 07677 (“Eagle”) and Spectrum Pharmaceuticals, Inc., a corporation organized under the laws of Delaware with offices at 11500 South Eastern Avenue, Suite 240, Henderson, Nevada 89052 (“Spectrum”). Each of Eagle and Spectrum is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
EX-10.2 2 d658391dex102.htm EX-10.2 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE...Co-Promotion Agreement • May 5th, 2020 • New York
This Co-Promotion Agreement (this Agreement) is entered into this 27th day of June, 2013 (the “Effective Date”), by and between Valeant Pharmaceuticals North America LLC, a Delaware limited liability company (“Valeant”), and Zogenix, Inc., a Delaware corporation (“Zogenix”). Each of Valeant and Zogenix is referred to herein, individually, as a “Party” and collectively, as the “Parties.”
CO-PROMOTION AGREEMENTCo-Promotion Agreement • March 1st, 2011 • Allergan Inc • Pharmaceutical preparations
This Co-Promotion Agreement (this “Agreement”) is made and entered into effective as of January 28, 2011, by and between MAP Pharmaceuticals, Inc., a Delaware corporation having an address at 2400 Bayshore Parkway, Suite 200, Mountain View, California 94043 (“MAP”), and ALLERGAN USA, Inc., a Delaware corporation having an address at 2525 Dupont Drive, Irvine, California 92612 (“ALLERGAN”). MAP and ALLERGAN are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
EX-10.1 2 d708097dex101.htm EX-10.1Co-Promotion Agreement • May 5th, 2020 • New York
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.
CO-PROMOTION AGREEMENTCo-Promotion Agreement • March 16th, 2020 • Tetraphase Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS CO-PROMOTION AGREEMENT (this “Agreement”) is entered into as of March 15, 2020 (the “Effective Date”) by and between ACELRX PHARMACEUTICALS, INC., a Delaware corporation, having an address of 351 Galveston Drive, Redwood City, California 94063 (hereinafter referred to as “AcelRx”), and TETRAPHASE PHARMACEUTICALS, INC., a Delaware corporation, having an address of 480 Arsenal Way, Suite 100, Watertown, Massachusetts 02472 (hereinafter referred to as “Tetraphase”). AcelRx and Tetraphase are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CO-PROMOTION AGREEMENTCo-Promotion Agreement • November 2nd, 2007 • Santarus Inc • Pharmaceutical preparations • New York
This Co-Promotion Agreement (this “Agreement”) is entered into this 24th day of August, 2007, by and between C.B. Fleet Company, Incorporated, a Virginia corporation, and its subsidiary C.B. Fleet Investment Corporation, a Delaware corporation (collectively “Fleet”) and Santarus, Inc., a Delaware corporation (“Santarus”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CO-PROMOTION AGREEMENT by and between...Co-Promotion Agreement • March 24th, 2023 • Provention Bio, Inc. • Pharmaceutical preparations • Delaware
This CO-PROMOTION AGREEMENT (this “Agreement”) is entered into as of October 4, 2022 (the “Effective Date”) by and between Provention Bio, Inc., a corporation organized and existing under the laws of Delaware, with its principal business address at 55 Broad Street, 2nd floor, Red Bank, NJ 07701, USA (“Provention”) and Genzyme Corporation, a corporation organized under the laws of the Commonwealth of Massachusetts, with its principal business address at 450 Water Street, Cambridge MA 02141, USA (“Sanofi”). Sanofi and Provention are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
Portions of this exhibit marked [*] are requested to be treated confidentially. CO-PROMOTION AGREEMENTCo-Promotion Agreement • November 9th, 2007 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • Delaware
This Co-Promotion Agreement (this “Agreement”) is entered into as of the 4th day of September, 2007, between Salix Pharmaceuticals, Ltd., a Delaware corporation, (hereinafter referred to as “SALIX”), and Eisai Inc., a Delaware corporation (hereinafter referred to as “EISAI”).
CO-PROMOTION AGREEMENT THIS CO-PROMOTION AGREEMENT (the "Agreement") is made as of December 21, 1999 by and between iParty Corp., a Delaware corporation ("iParty"), with an address at 41 East 11th Street, 11th Floor, New York, New York 10003 and...Co-Promotion Agreement • June 30th, 2000 • Iparty Corp • Services-computer integrated systems design • Delaware
CO-PROMOTION AGREEMENTCo-Promotion Agreement • November 9th, 2006 • Depomed Inc • Pharmaceutical preparations • California
This Co-Promotion Agreement (this “Agreement”) is entered into this 24th day of July, 2006 by and between Depomed, Inc., a California corporation (“Depomed”), and Esprit Pharma, Inc., a Delaware corporation (“Esprit”).
AMENDMENT NO. 1 TO CO-PROMOTION AGREEMENTCo-Promotion Agreement • August 1st, 2013 • Cubist Pharmaceuticals Inc • Pharmaceutical preparations
This AMENDMENT NO. 1 TO CO-PROMOTION AGREEMENT (the “Amendment”) is entered into on July 30, 2013 (the “Amendment Effective Date”), by and among Cubist Pharmaceuticals, Inc. (“Cubist”) and Optimer Pharmaceuticals, Inc. (“Optimer”). Cubist and Optimer may each be referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used but not defined in this Amendment have the meaning set forth in the Agreement.
CERTAIN INFORMATION HAS BEEN OMITTED IN ACCORDANCE WITH ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE MARKED [***]. CO-PROMOTION...Co-Promotion Agreement • May 7th, 2024 • Heron Therapeutics, Inc. /De/ • Pharmaceutical preparations
THIS CO-PROMOTION AGREEMENT (the “Agreement”) is dated this 5th day of January, 2024, but effective as of January 1, 2024 (the “Effective “Date”) by and between Heron Therapeutics, Inc., a Delaware corporation (hereinafter called “Heron”) and Crosslink Network, LLC, a Georgia limited liability company (hereinafter called “Co-Promoter”) (Heron and Co-Promoter sometimes hereinafter referred to individually as a “Party” and collectively as the “Parties”).
EXECUTION COPYCo-Promotion Agreement • August 9th, 2012 • Zogenix, Inc. • Pharmaceutical preparations • New York
This Co-Promotion Agreement (this “Agreement”) is made as of June 6, 2012 (the “Effective Date”), by and between Zogenix, Inc., a Delaware corporation (“Zogenix”), and Mallinckrodt LLC, a Delaware limited liability company (“Mallinckrodt”). Each of Zogenix and Mallinckrodt is referred to herein, individually, as a “Party” and, collectively, as the “Parties.”
THE REGISTRANT HAS APPLIED FOR CONFIDENTIAL TREATMENT OF CERTAIN PROVISIONS OF THIS EXHIBIT WITH THE SECURITIES AND EXCHANGE COMMISSION. THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE MARKED WITH ASTERISKS (*****) AND HAVE BEEN OMITTED. THE OMITTED...Co-Promotion Agreement • May 10th, 2005 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances • New York
This Agreement is made as of the 11TH day of April, 2005 (the “Effective Date”), by and between Auxilium Pharmaceuticals, Inc., a Delaware corporation, with principal offices at 160 W. Germantown Pike, Norristown, PA 19401 (“Auxilium”) and Oscient Pharmaceuticals Corp., a Massachusetts corporation, with principal offices at 1000 Winter Street, Suite 2200, Waltham, MA, 02451, (“Oscient”) (with each of Auxilium and Oscient referred to herein individually as a “Party” and collectively as the “Parties”).
FIRST AMENDMENT TO THE CO-PROMOTION AGREEMENTCo-Promotion Agreement • August 2nd, 2017 • Amarin Corp Plc\uk • Pharmaceutical preparations
This First Amendment (the “Amendment”) to the March 31, 2014 Co-Promotion Agreement is entered into and effective as of July 25, 2017, by and among Amarin Pharmaceuticals Ireland Limited, a company organized under the laws of Ireland (registered number 408912) with offices at 2 Pembroke House Upper Pembroke Street 28-32, Dublin 2, Ireland (“Amarin Ireland”), and Amarin Pharma, Inc., a Delaware corporation with offices at 1430 Route 206 North, Suite 101, Bedminster, NJ 07921 (“Amarin Pharma”, and collectively with Amarin Ireland, “Amarin”), on the one hand, and Kowa Pharmaceuticals America, Inc., a Delaware corporation with offices at 530 Industrial Park Blvd, Montgomery, AL 36117 (“Kowa”), on the other hand (collectively, the “Parties”).
CO-PROMOTION AGREEMENT dated as of August 31, 2005 by and between CEPHALON, INC. and McNEIL CONSUMER & SPECIALTY PHARMACEUTICALS, a Division of McNEIL-PPC, INC.Co-Promotion Agreement • November 9th, 2005 • Cephalon Inc • Pharmaceutical preparations • Delaware
This CO-PROMOTION AGREEMENT (“Agreement”) dated as of August 31, 2005 (the “Effective Date”), is made by and between McNEIL CONSUMER & SPECIALTY PHARMACEUTICALS, a division of McNEIL-PPC, Inc., a New Jersey corporation having its principal office at 7050 Camp Hill Road, Fort Washington, Pennsylvania 19034 (“McNeil”) and CEPHALON, INC., a Delaware corporation having its principal office at 41 Moores Road, Frazer, Pennsylvania 19355 (“Cephalon”). McNeil and Cephalon may be referred to as a “Party” or together as the “Parties”.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. CO-PROMOTION AGREEMENT by and between MILLENNIUM PHARMACEUTICALS, INC. and ORTHO BIOTECH INC. Dated: October 25, 2006Co-Promotion Agreement • March 1st, 2007 • Millennium Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
This CO-PROMOTION AGREEMENT (this “Agreement”) dated October 25, 2006 (the “Effective Date”), is entered into by and between MILLENNIUM PHARMACEUTICALS, INC. a Delaware corporation (“MLNM”) and ORTHO BIOTECH INC., a New Jersey corporation (“OBI”). MLNM and OBI are generically referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
ANDCo-Promotion Agreement • November 7th, 2005 • Allergan Inc • Pharmaceutical preparations • New York
CO-PROMOTION AGREEMENTCo-Promotion Agreement • January 11th, 2010 • Photomedex Inc • Electromedical & electrotherapeutic apparatus • Texas
THIS CO-PROMOTION AGREEMENT (“Agreement”), entered into as of this 7th day of January 2010, is by and between GALDERMA LABORATORIES, L.P., a Texas limited partnership, having as its principal place of business at 14501 North Freeway, Fort Worth, Texas 76177 (“PhotoMedex”), and PHOTOMEDEX, INC., a Delaware corporation, having as its principal place of business 147 Keystone Drive, Montgomeryville, PA 18936 (“PhotoMedex”) (each a “party”, collectively “parties”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE EXAGEN INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO EXAGEN INC. IF PUBLICLY DISCLOSED....Co-Promotion Agreement • March 16th, 2021 • Exagen Inc. • Services-medical laboratories
As contemplated in the Co-Promotion Agreement between Exagen and Janssen signed December 10, 2018, please find attached the final Baseline TRxU for October through December (4th Quarter) of 2020, which has been agreed upon by the Janssen and Exagen Teams. This Baseline TRxU include CVS/Anthem data for the zip codes covered by Exagen sale representatives.
CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION.Co-Promotion Agreement • August 21st, 2006 • Inyx Inc • Pharmaceutical preparations • Florida
This CO-PROMOTION AGREEMENT (“Agreement”) dated as of April 3, 2006 (the “Effective Date”), by and between TEAMM Pharmaceuticals, Inc. a Florida corporation with offices located at 2501 Aerial Center Parkway, Morrisville, NC (“TEAMM”) and Exaeris, Inc. a Delaware corporation with offices located at 403 Gordon Dr, Exton, PA 19341 (“Exaeris”)
Portions of this document have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed. Redacted portions are indicated with the...Co-Promotion Agreement • March 15th, 2021 • ONCOSEC MEDICAL Inc • Pharmaceutical preparations • New York
This CO-PROMOTION AGREEMENT (this “Agreement”) is entered into as of January 15, 2021 (the “Effective Date”) between OncoSec Medical Incorporated, a Nevada corporation with offices at 24 N Main Street, Pennington, NJ 08534 (“OncoSec”) and Sirtex Medical, Inc., a Delaware corporation with offices at 300 Unicorn Park Drive, Woburn, MA 01801 (“Sirtex”). OncoSec and Sirtex are referred to herein collectively as the “Parties” and each is referred to individually as a “Party.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. CO-PROMOTION AGREEMENT BY AND BETWEEN ICAGEN, INC. AND McNEIL CONSUMER & SPECIALTY PHARMACEUTICALS DIVISION OF McNEIL-PPC,...Co-Promotion Agreement • June 29th, 2004 • Icagen Inc • Pharmaceutical preparations
This Co-Promotion Agreement (this “Agreement”) is made effective as of June 14, 2004 (the “Effective Date”) by and between Icagen, Inc., a Delaware corporation having its principal place of business at 4222 Emperor Blvd., Suite 350, Durham, North Carolina 27703 (“Icagen”), and McNeil Consumer & Specialty Pharmaceuticals Division of McNeil-PPC, Inc., a New Jersey corporation having its principal place of business at 7050 Camp Hill Road, Fort Washington, Pennsylvania 19034 (“McNeil”).
CO-PROMOTION AGREEMENTCo-Promotion Agreement • May 18th, 2012 • PediatRx Inc. • Pharmaceutical preparations • California
This CO-PROMOTION AGREEMENT (this “Agreement”) is made as of February 21st, 2012 (the “Effective Date”), by and between Apricus Biosciences, Inc., a Nevada corporation (“Apricus”), and PediatRx Inc., a Nevada corporation (“PediatRx”). Each of Apricus and PediatRx is referred to herein individually as a “party” and collectively as the “parties.”
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED CO-PROMOTION AGREEMENTCo-Promotion Agreement • February 12th, 2021 • Urovant Sciences Ltd. • Pharmaceutical preparations • Delaware
This Co-Promotion Agreement (this “Agreement”) is entered into as of October 05, 2020 (the “Effective Date”) by and between Sunovion Pharmaceuticals Inc., a Delaware corporation, having a principle place of business at 84 Waterford Drive, Marlborough, Massachusetts, 01752, USA (“Sunovion”) and Urovant Sciences GmbH, a Swiss company, having a principle place of business at Viadukstrasse 8, 4051 Basel, Switzerland (“Urovant”). Sunovion and Urovant may individually be referred to as a “Party” and collectively as the “Parties.”
CO-PROMOTION AGREEMENTCo-Promotion Agreement • March 30th, 2007 • Auriga Laboratories, Inc. • Pharmaceutical preparations • California
This CO-PROMOTION AGREEMENT effective as of the 20th day of October, 2006 between AURIGA LABORATORIES, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 5555 Triangle Parkway, Suite 300, Norcross, GA 30092 (hereinafter referred to as “AURIGA”) and PHARMELLE L.L.C., a limited liability corporation organized and existing under the laws of the State of Missouri and having its principal office at 170 South William Dillard Drive, Building 3, Suite 109, Gilbert, AZ 85233 (hereinafter referred to as “PHARMELLE”).
AMENDMENT NO. 1 TO THE CO-PROMOTION AGREEMENTCo-Promotion Agreement • August 1st, 2013 • Auxilium Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”) is made as of July 31, 2013 (the “Amendment No. 1 Effective Date”) by and among GlaxoSmithKline LLC, a Delaware limited liability company (“GSK”) and Auxilium Pharmaceuticals, Inc., a Delaware corporation (“Auxilium”). GSK and Auxilium are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT NO. 1 TO CO-PROMOTION AGREEMENTCo-Promotion Agreement • January 6th, 2006 • Santarus Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO CO-PROMOTION AGREEMENT (the “Amendment”) by and between Santarus, Inc., a Delaware corporation (“Santarus”), and Otsuka America Pharmaceutical, Inc., a Delaware corporation (“Co-Promotion Partner”), is entered into as of January 6, 2006.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE EXAGEN INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO EXAGEN INC. IF PUBLICLY DISCLOSED....Co-Promotion Agreement • August 9th, 2021 • Exagen Inc. • Services-medical laboratories
As contemplated in the Co-Promotion Agreement between Exagen and Janssen signed December 10, 2018, please find attached the final Baseline TRxU for April through June (3th Quarter) of 2021, which has been agreed upon by the Janssen and Exagen Teams. This Baseline TRxU include CVS/Anthem data for the zip codes covered by Exagen sale representatives as of April 1, 2021, inclusive of the additional zip codes added.
THIRD AMENDMENT TO CO-PROMOTION AGREEMENTCo-Promotion Agreement • October 25th, 2005 • Medimmune Inc /De • Biological products, (no disgnostic substances)
This Third Amendment (the “THIRD AMENDMENT”), effective as of August 26, 2005 (the “THIRD AMENDMENT EFFECTIVE DATE”), is entered into by and between ABBOTT LABORATORIES, through its ROSS PRODUCTS DIVISION (“ABBOTT”), and MEDIMMUNE, INC. (“MEDIMMUNE”).
CO-PROMOTION AGREEMENTCo-Promotion Agreement • August 8th, 2013 • Zogenix, Inc. • Pharmaceutical preparations • New York
This Co-Promotion Agreement (this Agreement) is entered into this 27th day of June, 2013 (the “Effective Date”), by and between Valeant Pharmaceuticals North America LLC, a Delaware limited liability company (“Valeant”), and Zogenix, Inc., a Delaware corporation (“Zogenix”). Each of Valeant and Zogenix is referred to herein, individually, as a “Party” and collectively, as the “Parties.”
